Real-world study of her2-positive metastatic breast cancer in Kazakhstan
Part of Cancer, Skin clinical trials.
This study looks at real-world data from people with HER2-positive metastatic breast cancer in Kazakhstan to understand how anti-HER2 treatments (other than trastuzumab deruxtecan) are used and how well they work. If you were diagnosed between 2022 and 2023, this research may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HER2-positive (a marker that helps cancer grow).
- Your breast cancer has spread to other parts of the body (metastatic).
- You are currently receiving or have started anti-HER2 treatment, but not the drug trastuzumab deruxtecan (Enhertu).
- You were diagnosed with metastatic breast cancer between January 2022 and December 2023.
- You are 18 years or older.
- You have at least 24 months of follow-up data in your medical records (or you died, moved, or stopped therapy within that time).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This study tracks how patients with HER2-positive early-stage breast cancer receive treatment and stick to their treatment plan after their care moves to local hospitals. The trial helps doctors understand whether patients follow through with their recommended therapy when treated closer to home.
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
This study looks at how well the drug Trastuzumab Deruxtecan works and how safe it is in real-world patients with advanced stomach or gastroesophageal cancer whose tumors are HER2-positive. The goal is to gather more information beyond what was learned in clinical trials.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.